{"id":645460,"date":"2025-12-21T03:24:29","date_gmt":"2025-12-21T03:24:29","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/645460\/"},"modified":"2025-12-21T03:24:29","modified_gmt":"2025-12-21T03:24:29","slug":"astrazeneca-plc-azn-announces-approval-of-saphnelo-by-the-european-union","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/645460\/","title":{"rendered":"AstraZeneca PLC (AZN) Announces Approval of Saphnelo by the European Union"},"content":{"rendered":"\n

\u200bAstraZeneca PLC (NASDAQ:AZN<\/a>) is one of the Best Non-US Stocks to Buy According to Hedge Funds<\/a><\/strong>. On December 16, AstraZeneca PLC (NASDAQ:AZN) announced the approval of its Saphnelo by the European Union for subcutaneous self-administration to treat adults with systemic lupus erythematosus along with the standard therapy.<\/p>\n

\u200bManagement noted that the approval is based on the positive results from the Phase III TULIP-SC trial and follows a positive opinion from the Committee for Medicinal Products for Human Use. The trial showed that Saphnelo, along with the standard therapy, resulted in a meaningful reduction in disease activity compared to the placebo. This marks an important breakthrough. SLE is an autoimmune condition impacting more than 3.4 million people internationally, and patients in Europe are two to three times greater risk of death compared to the rest of the world.<\/p>\n

\"\" <\/p>\n

\u200bThat said, Wall Street is also bullish on AstraZeneca PLC (NASDAQ:AZN). Recently, on December 10, Rajesh Kumar from HSBC reiterated a Buy rating on the stock and raised the price target from $95 to $108. Earlier, on December 9, Steve Scala from TD Cowen also reiterated a Buy rating on the stock with a $105 price target.<\/p>\n

\u200bRajesh Kumar of HSBC noted that he remains optimistic on the pharma group, considering that the sector is set to outperform in 2026. On the other hand, Steve Scala from TD Cowen noted the company\u2019s promising new products and strong pipeline as one of the key reasons behind the bullish sentiment.<\/p>\n

\u200bAstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians.<\/p>\n

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b><\/a>.<\/p>\n

READ NEXT: <\/b>30 Stocks That Should Double in 3 Years<\/b><\/a> and <\/b>

Insider Monkey<\/b><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"\u200bAstraZeneca PLC (NASDAQ:AZN) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December…\n","protected":false},"author":2,"featured_media":645461,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[30888,2000,299,5187,1699,198106,198109,198108,198107],"class_list":{"0":"post-645460","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-astrazeneca-plc","9":"tag-eu","10":"tag-europe","11":"tag-european","12":"tag-european-union","13":"tag-rajesh-kumar","14":"tag-saphnelo","15":"tag-steve-scala","16":"tag-systemic-lupus-erythematosus"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115755421749223777","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/645460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=645460"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/645460\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/645461"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=645460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=645460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=645460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}